Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.81 |
| ▸ | NPC1 | O15118 | 8/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.81 |
| ▸ | HTT | P42858 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30851501 | 0.90 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL11202950 | 0.90 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL31308926 | 0.83 | SMN1; SMN2 (0.62) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL6185781 | 0.82 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL21834403 | 0.81 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL28194618 | 0.80 | POLB (0.56) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL27467650 | 0.80 | RAB9A (0.80) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL2089515 | 0.80 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2HTTPOLB | |
| SCHEMBL2089517 | 0.80 | KMT2A (0.52) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL5950253 | 0.80 | KMT2A (0.61) | RAB9ANPC1SMN1; SMN2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | RAB9A 983/4885NPC1 573/4885SMN1; SMN2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.